SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation S494R


Basic Characteristics of Mutations
Mutation Site S494R
Mutation Site Sentence TABLE
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype B.1.1.7
Viral Reference -
Functional Impact and Mechanisms
Disease -
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 35568025
Title LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Author Westendorf K,Zentelis S,Wang L,Foster D,Vaillancourt P,Wiggin M,Lovett E,van der Lee R,Hendle J,Pustilnik A,Sauder JM,Kraft L,Hwang Y,Siegel RW,Chen J,Heinz BA,Higgs RE,Kallewaard NL,Jepson K,Goya R,Smith MA,Collins DW,Pellacani D,Xiang P,de Puyraimond V,Ricicova M,Devorkin L,Pritchard C,O'Neill A,Dalal K,Panwar P,Dhupar H,Garces FA,Cohen CA,Dye JM,Huie KE,Badger CV,Kobasa D,Audet J,Freitas JJ,Hassanali S,Hughes I,Munoz L,Palma HC,Ramamurthy B,Cross RW,Geisbert TW,Menachery V,Lokugamage K,Borisevich V,Lanz I,Anderson L,Sipahimalani P,Corbett KS,Yang ES,Zhang Y,Shi W,Zhou T,Choe M,Misasi J,Kwong PD,Sullivan NJ,Graham BS,Fernandez TL,Hansen CL,Falconer E,Mascola JR,Jones BE,Barnhart BC
Journal Cell reports
Journal Info 2022 May 17;39(7):110812
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.